Bioverativ Therapeutics Inc. (United States)

Bioverativ Therapeutics, now part of Sanofi, was a biopharmaceutical company focused on hemophilia treatments. The company developed ELOCTATE (efmoroctocog alfa) for hemophilia A and ALPROLIX (eftrenonacog alfa) for hemophilia B, extended half-life clotting factor therapies that reduce treatment burden for bleeding disorder patients. Sanofi continues advancing hemophilia care through Bioverativ’s innovative rare blood disorder research.